PharVision Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

PharVision Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,522	Closed	-$581K	–	957
2025 Q3	$581K	Buy	+20,522	New	+$614K	0.33%	12

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's RIGL Position: Q4 2025 in Review

PharVision Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 20,522 shares — an estimated $581K sold.

PharVision Advisers first reported a position in RIGL in Q3 2025 and held it in 1 quarter. The position peaked at $581K in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

PharVision Advisers reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 20,522 Rigel Pharmaceuticals shares in Q4 2025, an estimated $581K.
PharVision Advisers first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Rigel Pharmaceuticals position peaked at $581K in Q3 2025.
193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.